The estimated Net Worth of Matthew T Cooper is at least 47 千$ dollars as of 2 September 2020. Dr Cooper owns over 9,250 units of Progenity stock worth over 47,017$ and over the last 4 years he sold PROG stock worth over 0$.
Sign up
Dr D PROG stock SEC Form 4 insiders trading
Dr has made over 1 trades of the Progenity stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 9,250 units of PROG stock worth 79,088$ on 2 September 2020.
The largest trade he's ever made was buying 9,250 units of Progenity stock on 2 September 2020 worth over 79,088$. On average, Dr trades about 1,028 units every 0 days since 2020. As of 2 September 2020 he still owns at least 53,428 units of Progenity stock.
You can see the complete history of Dr Cooper stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Matthew T. Cooper M.B.A., Ph.D. biography
Dr. Matthew T. Cooper M.B.A., Ph.D. is the Chief Scientific Officer at Progenity.
How old is Dr D?
Dr D is 48, he's been the Chief Scientific Officer of Progenity since . There are 6 older and 1 younger executives at Progenity. The oldest executive at Progenity, Inc. is George Gianakopoulos, 59, who is the Sr. VP of Sales.
What's Dr D's mailing address?
Matthew's mailing address filed with the SEC is C/O PROGENITY, INC., 4330 LA JOLLA VILLAGE DRIVE, SUITE 200, SAN DIEGO, CA, 92122.
Insiders trading at Progenity
Over the last 4 years, insiders at Progenity have traded over 0$ worth of Progenity stock and bought 34,001,547 units worth 176,045,049$ . The most active insiders traders include Capital Management, Lp Ferr...、Opportunities Fund (A) Lp A...、Opportunities Fund (A) Lp A.... On average, Progenity executives and independent directors trade stock every 24 days with the average trade being worth of 1,994,758$. The most recent stock trade was executed by Capital Management, Lp Ferr... on 14 June 2021, trading 8,097,166 units of PROG stock currently worth 20,000,000$.
What does Progenity do?
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
What does Progenity's logo look like?
Complete history of Dr Cooper stock trades at Progenity
Progenity executives and stock owners
Progenity executives and other stock owners filed with the SEC include:
-
Eric d'Esparbes,
Chief Financial Officer -
Damon Silvestry,
Chief Operating Officer -
Robyn Hatton,
VP of HR -
George Gianakopoulos,
Sr. VP of Sales -
Hutan Hashemi J.D.,
Chief Compliance Officer -
Clarke Neumann,
Sr. VP, Gen. Counsel & Sec. -
Troy Seelye,
Chief Information Officer -
Dr. Matthew T. Cooper M.B.A., Ph.D.,
Chief Scientific Officer -
Eric Fox,
VP of Fin. & Accounting & Treasurer -
Aditya P. Mohanty,
CEO & Director -
Jill Ann Howe,
Director -
Surbhi Sarna,
Director -
Hutan Hashemi,
Chief Compliance Officer -
Eric D Esparbes,
Chief Financial Officer -
Clarke Neumann,
See Remarks -
Harry Stylli,
Chairman & CEO -
Opportunities Fund (A) Lp A...,
-
Capital Management, Lp Ferr...,
-
Troy Seelye,
Chief Information Officer -
Sami Shihabi,
Chief Commercial Officer -
George Gianakopoulos,
Senior Vice President of Sales -
Jeffrey D. Alter,
Director -
Capital Management, Lp Ferr...,
-
Samuel R Md Nussbaum,
Director -
Lynne Powell,
Director -
Opportunities Fund (A) Lp A...,
-
John T. Bigalke,
Director -
Brian L. Kotzin,
Director -
Damon Silvestry,
See Remarks -
Aditya P. Mohanty,
Chief Executive Officer -
Matthew T Cooper,
General Manager, Diagnostics